Ani Balmanoukian, M.D.
Dr. Ani Balmanoukian is a hematologist and oncologist who is currently affiliated with Cedars-Sinai Marina del Rey Hospital. She received her medical degree from the New York Medical College School of Medicine and also has a Bachelor of Science in Psychological Science and a Bachelor of Arts in Art History from UCLA. Dr. Ani Balmanoukian was on the Provost's Honor list and graduated Cum Laude. The physician's clinical areas of research include novel targeted agents, immunotherapeutics, and early drug development. She has presented data at prestigious medical meetings and has had publications in the New England Journal of Medicine, Lancet Oncology, and the Journal of Clinical Oncology. Dr. Ani Balmanoukian is committed to excellence in comprehensive healthcare and believes in promoting it through state-of-the-art therapy while ensuring compassionate care. The physician has over 20 years of professional experience. Prior to practicing in California, Dr. Ani Balmanoukian had a medical license for Maryland. She is certified by the American Board of Internal Medicine.
Insurance Accepted
- Aetna
- Blue Cross / Blue Shield
- CareFirst BCBS
- Cigna
- Humana
- MultiPlan
- United Healthcare
Languages Spoken
- Armenian
- English
Education & Training
Medical Degree
New York Medical College
Internship(s)
The John Hopkins Hospital
Residency(ies)
The John Hopkins Hospital
Fellowship(s)
The John Hopkins Hospital
Publications & Media
-
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Segal, N.H., Ou, S., Balmanoukian, A., Fury, M.G., Massarelli, E., Brahmer, J.R., Weiss, J., Schöffski, P., Antonia, S.J., Massard, C., Zandberg, D.P., Khleif, S.N., Xiao, F., Rebelatto, M.C., Steele, K.E., Robbins, P.B., Angra, N., Song, X., Abdullah, S., Butler, M.
-
The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas.
Balmanoukian, A., Ye, X., Herman, J., Laheru, D., Grossman, S.A.
-
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Leighl, N.B., Hellmann, M.D., Hui, R., Carcereny, E., Felip, E., Ahn, M.J., Eder, J.P., Balmanoukian, A.S., Aggarwal, C., Horn, L., Patnaik, A., Gubens, M., Ramalingam, S.S., Lubiniecki, G.M., Zhang, J., Piperdi, B., Garon, E.B.
-
Managing the patient with borderline resectable lung cancer.
Balmanoukian, A., Ettinger, D.S.
-
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.
Balmanoukian, A., Zhang, Z., Jeter, S., Slater, S., Armstrong, D.K., Emens, L.A., Fetting, J.H., Wolff, A.C., Davidson, N.E., Jacobs, L., Lange, J., Tsangaris, T.N., Zellars, R., Gabrielson, E., Stearns, V.
-
Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.
Grossman, S.A., Ellsworth, S., Campian, J., Wild, A.T., Herman, J.M., Laheru, D., Brock, M., Balmanoukian, A., Ye, X.
-
Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.
Ellsworth, S., Balmanoukian, A., Kos, F., Nirschl, C.J., Nirschl, T.R., Grossman, S.A., Luznik, L., Drake, C.G.